Hers vs Noom: How the Two GLP-1 Telehealth Programs Compare

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

This is an independent editorial review. PlexusDx holds no commercial relationship with Hers, Noom, or their parent companies, and no affiliate links or compensation are involved in this comparison.

Shoppers who type "Hers vs Noom" are usually trying to settle a single decision: which telehealth brand should handle a GLP-1 weight program. Both sit inside a crowded April 2026 market of dozens of competing services, so this piece skips the hype and lays out how each one is built, where they genuinely differ, and one metabolic factor neither brand puts on the table.

Two telehealth models, one question

Hers and Noom both promise convenient, virtual access to weight-management medication, yet they arrive at that promise from different starting points. Hers grew out of a direct-to-consumer prescribing brand, while Noom built its name on behavior-change coaching before layering medication on top. Understanding that origin story explains most of what separates them today.

How Hers structures its weight program

Hers (Hims & Hers Health) runs on a subscription telehealth chassis. Services in this format usually pair a virtual clinical evaluation with a provider-issued prescription, dispensing either an FDA-approved branded GLP-1 or a compounded semaglutide or tirzepatide through a licensed compounding pharmacy pathway. Program specifics live on Hers’s official website, which is the authoritative source for what is currently offered.

How Noom structures its weight program

Noom (Noom, Inc.) leads with an app-based subscription and treats medication as an add-on rather than the headline. Its coaching and food-logging framework wraps around any prescription a clinician writes. Because medication tiers and pricing shift often, the current details belong on Noom’s official website as of the date you read this.

Where the two programs actually diverge

The meaningful contrasts are structural, not pharmacological: how heavily each leans on coaching, whether the medication is branded or compounded, what the subscription bundles, and which provider type reviews your intake. Someone who wants habit coaching alongside a prescription may gravitate toward Noom; someone who wants a leaner prescribe-and-ship experience may prefer Hers. Neither arrangement changes the underlying biology.

The compound does the work, not the brand

Both services operate within the GLP-1 receptor agonist space. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the GIP/GLP-1 dual agonist tirzepatide act on appetite regulation, satiety signaling, and gastric emptying. The pharmacology is identical across any legitimate program — the trial record backs the molecule, not the storefront. Landmark programs include STEP (semaglutide, NEJM 2021), SURMOUNT (tirzepatide, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024), with effect sizes varying by dose and population.

The genetic layer both programs skip

Neither Hers nor Noom examines the upstream genetics that frame how your body meets any GLP-1 compound. Variants in GLP1R — the gene encoding the GLP-1 receptor that every compound in this class targets — along with FTO, MC4R, and TCF7L2, describe your baseline appetite, satiety, and glucose-handling terrain. These are pathway-level markers: they never predict response to a particular drug, but they map the biology a clinician is prescribing into. The Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights, giving you that context before you commit to any program.

Choosing between them — and a third consideration

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. The distinguishing move is pairing the protocol with genetic context most telehealth brands omit — the test before you invest approach that turns a purchase decision into an informed conversation with your provider.

Not affiliated: PlexusDx is not affiliated with Hers or Noom and holds no commercial relationship with the companies reviewed in this article.

Related reading on PlexusDx: GLP 1 Receptor Agonist, GLP 1 Drugs, GLP 1 Hormone, What Is GLP 1.

Disclaimer: This article is educational. PlexusDx is not affiliated with Hers or Noom and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols — this review compares approaches in the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Compare the PlexusDx approach: see the Weight Management Protocols — or start upstream and take the Precision Peptide Genetic Test to read your GLP-1 pathway first.

Frequently Asked Questions

Is Hers or Noom the better choice for weight loss?

Neither wins on merit alone. Both run inside the GLP-1 telehealth space with comparable clinical structures. The right fit hinges on whether you want coaching-forward support, a leaner prescribing flow, a particular medication, or a specific price tier. Review each brand’s own site to match those features to your goals.

Do Hers and Noom prescribe the same medications?

Both can route GLP-1 receptor agonist prescriptions through telehealth. Differences fall in dispensing pathway — branded FDA-approved products versus compounded alternatives — subscription design, and provider type. The pharmacology itself is set by the compound, not by whichever platform arranges the prescription and shipment.

Does the Precision Peptide Genetic Test say which service to pick?

No. The test never ranks telehealth brands or forecasts drug response. It analyzes pathway-level variants in GLP1R, FTO, MC4R, and TCF7L2 that shape baseline GLP-1 biology — context that stays relevant no matter which service, Hers or Noom, ultimately writes the prescription for you.

How does PlexusDx differ from both brands?

PlexusDx supplies semaglutide and tirzepatide through its Weight Management Protocols and pairs them with upstream genetic insight via the Precision Peptide Genetic Test. That pathway-level layer — mapping FTO, GLP1R, and MC4R variants — is the piece Hers, Noom, and most GLP-1 telehealth programs leave out.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education